T rimethylamine-N-oxide (TMAO) has gained much attention recently because of its potential adverse effects on atherosclerosis and cardiovascular disease (CVD).
1,2 TMAO is a gut microbial-host cometabolite of dietary trimethylamines (mainly choline and carnitine). Its metabolism involves 3 steps: (1) gut microbial degradation of dietary trimethylamines, (2) conversion of trimethylamine to TMAO by host liver enzymes, and (3) kidney excretion of circulating TMAO in urine. Studies from the Cleveland Clinic have shown that TMAO promotes atherosclerosis in mice by inhibiting reverse cholesterol transport, activating macrophages, and increasing platelet activity and thrombosis, [3] [4] [5] [6] whereas inhibiting TMAO production reduces the formation of atherosclerotic lesions. 7 Their studies have also shown that elevated TMAO levels predict worse CVD and death outcomes among cardiology patients, independent of traditional risk factors. 5, 6 Given those promising findings, an increasing number of studies have investigated the associations of TMAO and its precursor metabolites with CVD outcomes, such as major adverse cardiovascular events (MACE; including myocardial infarction, stroke, heart failure, other CVDs, and death). [8] [9] [10] [11] A recent meta-analysis reported a relative risk of 1.62 (95% CI, 1.45-1.80) for MACE, comparing the highest and lowest levels of TMAO. 2 However, as the authors pointed out, MACE is a composite of clinical events, the definition of which varied across studies and often included death due to any cause. Furthermore, all published prospective studies were clinical cohorts of high-risk individuals, such as patients with prior CVDs or chronic kidney disease (CKD). Reverse causality and confounding bias caused by existing diseases and their treatments are of major concern. [12] [13] [14] [15] To our knowledge, no studies have examined, in general populations, whether TMAO is associated with risk of developing CVD, especially coronary heart disease (CHD)-the leading cause of death worldwide. 16 In addition, TMAO food sources vary across populations. For most Americans, dietary choline and carnitine come mostly from red meat, poultry, eggs, and dairy. 17, 18 However, choline is also abundant in fish, shellfish, and legumes, 19 and TMAO is naturally abundant in seafood (no microbial metabolism required). 20, 21 It has been found that Hispanic/ Latino people consume more choline from legumes than nonHispanic white people 22 ; TMAO level is associated with intake of fish and dairy, but not meat, in Europeans; and among Chinese adults, nearly 50% of dietary choline is plant-based, mostly from soy foods. 23 All published prospective studies on the TMAO-CVD association, thus far, have been from Western populations (mostly white Americans). Data from populations with different habitual diets and potentially differentiated microbial production of TMAO would help advance our understanding of the nature of the TMAO-CVD association.
To address the research gap regarding whether TMAO is associated with incident CHD in general-risk populations and in nonwhite populations, we conducted a case-control study nested within 2 cohorts of Chinese adults: the SWHS (Shanghai Women's Health Study) and the SMHS (Shanghai Men's Health Study). Baseline urinary concentrations of TMAO, choline, betaine, and carnitine were quantified, providing an integrated measure of the diet-microbial host cometabolism of TMAO. We evaluated the associations of these metabolites with dietary intake, lifestyle factors, CVD biomarkers (eg, blood lipids and high-sensitivity C-reactive protein [hs-CRP]), and risk of CHD, with adjustments for potential confounders.
Methods Study Population
The SWHS and SMHS are 2 population-based, prospective cohorts of 74 941 women and 61 480 men (aged 40-74 years) who lived in Shanghai, China, between 1996 and 2006. 24, 25 At , an in-person interview was conducted to collect information on sociodemographics, diet, lifestyle, medical history, and anthropometrics. Biological samples, including peripheral blood and spot urine, were collected from willing study participants. Overall, blood samples were available from 75% of the participants, and urine samples were available from 88%. All samples were transported in a Styrofoam box with ice packs (0-4°C), processed within 6 hours of collection, and stored at À80°C until laboratory assays. Participants have been followed-up for chronic disease outcomes via home visits every 2 to 4 years (overall follow-up rates >92%) and for death outcomes via linkages to the Shanghai Vital Statistic Registry annually (complete rates >99%). Both cohorts are approved by the institutional review boards of the Shanghai Cancer Institute and Vanderbilt University. All participants provided informed consent. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Information regarding the data sharing policy for the SWHS and SMHS can be found at https://www.mc.vanderbilt.edu/ swhs-smhs/.
Clinical Perspective
What Is New?
• This study is the first conducted in a general population showing that trimethylamine-N-oxide (TMAO), a diet-derived, gut microbial-host cometabolite, is positively associated with risk of developing coronary heart disease (CHD), after adjustment for traditional CHD risk factors.
• The TMAO-CHD association was found among participants with or without existing metabolic conditions but was more pronounced among diabetic participants.
• Urinary TMAO level was significantly associated with consumption of deep-fried meat or fish, suggesting a potential interaction between meat cooking methods and the gut microbiota.
What Are the Clinical Implications?
• Elevated TMAO may be a novel risk factor for CHD in general and in high-risk populations.
• Possible interactions of TMAO with diabetes mellitus history and dietary intake imply potential applications of the dietgut microbiota-host interplay in preventing cardiovascular disease.
A Nested Case-Control Study of CHD
We drew participants with CHD, including nonfatal myocardial infarction and fatal CHD, and controls from cohort participants who provided a blood and urine sample and reported no history of CHD, stroke, or cancer at baseline. Details on the study design were published previously. 26 In brief, potential cases of incident myocardial infarction were identified during follow-up visits, and those participants' medical records were reviewed by physicians to adjudicate the diagnosis. Fatal CHD cases were identified by reviewing participants' medical records and death certificates with CHD listed as the underlying cause of death (International Classification of Diseases, Ninth Revision [ICD-9] codes 410-414). A total of 377 cases of confirmed, incident CHD were included. For each case, 2 controls were selected from eligible cohort participants who were free of CHD at the time of case diagnosis, matched by sex, age (AE2 years), date of sample collection (AE1 month), time of sample collection (morning or afternoon), use of antibiotics in past 7 days (yes or no), and menopausal status (for women). For the current study, we further excluded participants who reported extreme calorie intake (n=12; <500 or >3500 kcal/day for women; <800 or >4200 kcal/day for men) or history of kidney disease (n=59) or who had blood or protein in their urine based on a dipstick test (n=31). After exclusion, 275 cases remained, and we randomly selected 1 matched control for each case for the current metabolomics study given limited study funding. Table 1 . Calibration curves were created for each metabolite with detection limits for TMAO (5 lmol/L), choline and betaine (10 lmol/L), and carnitine (500 nmol/L). Interassay coefficients of variation were found for TMAO (4.5%), choline (3.0%), betaine (5.9%), and carnitine (8.5%). Urinary creatinine was measured using a Roche-Cobas MiraPlus chemistry analyzer. Plasma concentrations of total cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, and hs-CRP were measured, as described previously. 26 To control for batch variation and potential bias, samples of each case-control pair were analyzed in the same assay run with a random arrangement, and laboratory personnel were blind to the case-control status of the samples.
Laboratory Assays

Covariate Assessments
Detailed information was collected on participants' sociodemographics (eg, age, sex, and education), lifestyle (eg, cigarette smoking, alcohol drinking, and physical activity), medical history (eg, diabetes mellitus, hypertension, and dyslipidemia), and diet (both habitual and recent food intake) at study enrollment. Specifically, food intake during the past 12 months was assessed using validated semiquantitative food-frequency questionnaires. 27 on estimation of trimethylamine nutrient intake among our cohorts were described previously. 23 Total trimethylamine intake was the sum of choline, betaine, and carnitine intake. Trimethylamine intake from animal-or plant-based foods was estimated. We also evaluated participants' overall dietary quality by their adherence to Dietary Approaches to Stop Hypertension (DASH), 30 which has been associated with %40%
reduced CVD mortality among our cohorts. 31 Furthermore, participants were asked questions regarding intake of selected foods in the past 7 days and the past 24 hours before biospecimen collection, including the number of times that soy foods, deep-fried wheat or rice products, and deep-fried or stir-fried meat or fish (including red meat, poultry, and fish) were consumed.
Statistical Analyses
A series of data-processing procedures was performed before analysis. Undetected metabolite concentrations (n=3 for TMAO and n=5 for betaine) were assigned half of the minimum of nonmissing values. Metabolite concentrations were standardized by urinary creatinine concentration and expressed as nanomoles per milligram of creatinine. Levels of metabolites, blood lipids, and hs-CRP were log-transformed to improve normality of their distributions. Nutrient and food intakes were adjusted for total caloric intake and standardized to intakes per 2000 kcal. Missing data on covariates (all found in <10 participants) were imputed by the median for continuous variables and the mode for categorical variables. Baseline characteristics and metabolite levels were compared among cases and controls using a paired t test for continuous variables and the Cochran-Mantel-Haenszel test for categorical variables. Associations of trimethylamine metabolites with baseline characteristics, CVD biomarkers, and dietary intakes were evaluated using a general linear model with adjustment for age, sex, time since last meal (hours), recent use of antibiotics (yes or no), and total calorie intake (diet-related analyses only). In the general linear model, metabolites, biomarkers, and dietary intakes were standardized by meanAESD. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% CIs for CHD risk related to levels of trimethylamine metabolites by quartiles and per SD increase. Quartiles were based on sexspecific distributions among controls. P for trend was obtained by modeling the median value of each quartile as a continuous variable. Covariates in model 1 included age, obesity (body mass index ≥27.5 according to World Health Organization [WHO] criteria for Asians), 32 DASH diet score, leisure-time exercise (metabolic equivalents), smoking pack-years, history of hypertension (including use of antihypertensive medications), history of diabetes mellitus, and total menstruation years in women. Model 2 further included central obesity (waist-hip ratio ≥0.85 for women and ≥0.95 for men, according to WHO criteria for Asians), 33 dyslipidemia (self-reported history or measured total cholesterol ≥240 mg/dL, LDL ≥160 mg/dL, HDL <50/40 mg/ dL for women/men, or triglycerides ≥200 mg/dL, according to the US National Cholesterol Educational Program), 34 and lowgrade inflammation (hs-CRP >1 mg/L, median among controls, similar to suggested optimal cutoff for hs-CRP in general Chinese populations). 35 Model 3 further included intake of saltwater fish and shellfish (sex-specific quartile) and deep-fried meat or fish (times per week). Covariates were chosen based on our prior knowledge of major CHD risk factors and their associations with TMAO level and CHD risk in our cohorts. Stratified analyses were conducted to evaluate the TMAO-CHD association by CHD risk factors and TMAO food sources (eg, meat versus fish versus plant foods). A product term of metabolite levels (dichotomized by sex-specific median among controls or as a continuous variable) with the stratified variable was added to the fully adjusted model. P value for interaction was obtained from the product term; meanwhile, OR and 95% CI in each stratum were obtained by specifying the level of stratified variable. Sensitivity analyses were conducted among participants without recent use of antibiotics (241 case-control pairs). Restricted cubic splines were used to test potential nonlinear associations. Three knots at the 5th, 50th, and 95th percentiles were chosen based on the goodness of model fit (Akaike information criterion). Data analyses were performed using SAS (version 9.4; SAS Institute). A 2-sided P<0.05 was considered statistically significant.
Results
Compared with controls, men and women who developed CHD had significantly higher waist-hip ratios, prevalence of hypertension, and hs-CRP levels at baseline (Table 2 ). Women with CHD had a higher prevalence of diabetes mellitus but lower DASH diet scores and shorter total years of menstruation; men with CHD had higher body mass index and total and LDL cholesterol, and triglyceride levels. No significant case-control difference was found in cigarette smoking, selfreported history of dyslipidemia, intake of trimethylamine nutrients, or urinary levels of TMAO and other metabolites.
We observed significant positive associations of TMAO level (b reflects SD changes in log-TMAO) with female sex (b=0.19; Table 3 ), central obesity (b=0.21), dyslipidemia (lipid-defined, b=0.24), and high hs-CRP (b=0.19) and negative associations with hypertension or antihypertensive medication (b=À0. 19) and antibiotics (b=À0.34). We also observed significant associations of choline and betaine with history of diabetes mellitus (b=0.60 and b=1.21, respectively), betaine with central obesity (b=0.22) and history of dyslipidemia (b=0.30), and carnitine with menstruation years in women (b=À0.27). TMAO and related metabolites generally showed no associations with lifestyles including smoking, alcohol drinking, exercise, and DASH score. Among dietary intakes, TMAO was associated with animal-based trimethylamine (b=0.09) but not plant-based trimethylamine and with saltwater fish (b=0.19) and shellfish (b=0.08) but not freshwater fish, red meat, poultry, eggs, dairy, soy foods, or legumes. TMAO was strongly associated with deep-fried meat and fish consumption (b=0.36 for once or more per week versus none, b=0.25 for consumption 1 additional time per week, and b=0.41 for consumption 1 additional time in past 24 hours). In contrast, TMAO was not associated with stirfried meat or fish or deep-fried wheat or rice products, and other metabolites were not associated with deep-fried meat or fish.
Urinary TMAO, but not its precursor metabolites, was associated with risk of CHD ( Table 4 ). The OR for the highest versus lowest quartiles of TMAO was 1.91 (95% CI, 1.08- diabetes mellitus modified the associations of all TMAOrelated metabolites with CHD (interaction, all P<0.05; Table 5 ). Strong positive associations were found among diabetic patients, and comparing greater than or equal to versus less than the median gave ORs of 6.21, 5.20, 5.32, and 3.79 for TMAO, choline, betaine, and carnitine, respectively. Among nondiabetic participants, only TMAO showed a significant association, with fully adjusted ORs of 1.56 (95% CI, 1.00-2.43) in comparing greater than or equal to versus less than the median and 1.26 (95% CI, 1.00-1.59) per SD increase (Table 6 ). The TMAO-CHD association appeared stronger among individuals with low intake of plant-based trimethylamine (OR: 2.20; 95% CI, 1.23-3.94) or low intake of fiber (OR: 2.06; 95% CI, 1.14-3.72) than their counterparts (both interactions, P=0.10). The TMAO-CHD association was not influenced by levels of precursor metabolites, but precursor metabolites showed trends of positive associations when TMAO level was high (greater than or equal to the median). If considered jointly, participants with a high TMAO level (high-TMAO producers) showed an OR of 1.66 (95% CI, 0.98-2.81) for CHD compared with those who had a low TMAO level despite a high precursor level (low-TMAO producers). Results were similar when participants who recently used antibiotics were excluded.
Discussion
Our study showed, for the first time, that TMAO, a dietderived, gut microbial-host cometabolite, is associated with a higher risk of developing CHD in a general population. The positive association was observed after adjusting for major CHD indicates coronary heart disease; DASH, Dietary Approaches to Stop Hypertension; OR, odds ratio; TMA, trimethylamine; TMAO, trimethylamine N-oxide. *Sex-specific quartiles among controls. Conditional logistic regression was conducted by matched case-control pair. Model 1 was adjusted for age, obesity, DASH diet score, leisure-time exercise (metabolic equivalents), smoking pack-years, history of hypertension (including use of antihypertensive medications), history of diabetes mellitus, and total menstruation years in women. Model 2 further included central obesity, dyslipidemia, and low-grade inflammation. Model 3 further included intakes of saltwater fish and shellfish (sex-specific quartile) and deepfried meat or fish (times/wk).
CVD risk factors and among individuals without metabolic conditions such as diabetes mellitus, hypertension, dyslipidemia, and low-grade inflammation. However, presence of diabetes mellitus significantly strengthened the TMAO-CHD association: high TMAO level was associated with a >6-fold risk of CHD among diabetic participants but a 1.6-fold risk among nondiabetic participants. This study is also the first conducted in a non-Western population, whose TMAO food sources differed from Western populations included in prior studies. We found that TMAO was not associated with plantbased trimethylamine intake, was weakly associated with animal-based trimethylamine, was moderately associated with seafood, and was strongly associated with deep-fried meat or fish. TMAO was also associated with central obesity, dyslipidemia, and low-grade inflammation. However, the TMAO-CHD association remained significant after controlling for these intermediate risk factors and dietary factors. In contrast, TMAO's precursor metabolites (choline, betaine, and carnitine) were not associated with risk of CHD except among diabetic individuals. The gut microbiota has been recognized as playing an important role in human cardiovascular health. [36] [37] [38] Disturbed gut microbiota, common in industrialized countries and becoming common in fast-developing countries, has been linked with chronic diseases, including CHD. 39 Long-term diet is one of the most important determinants of the gut microbiota. 36, 38, 40 Diet not only shapes the composition and functionality of gut microbiota but also provides substrates for microbial metabolism. The gut microbial metabolites are able to trigger host signaling pathways and thus affect human cardiovascular health. 41, 42 Specifically, TMAO, a gut microbial metabolite of dietary choline and carnitine, has been shown recently to promote atherosclerosis and to predict CVD and death events in clinical cohorts. 1, 2 In 2011-2013, Cleveland
Clinic investigators first reported that elevated plasma TMAO (the highest versus lowest quartiles) was associated with a %50% increased risk of MACE (myocardial infarction, stroke, or death) among cardiology patients, after adjusting for a wide CHD indicates coronary heart disease; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio; TMA, trimethylamine; TMAO, trimethylamine N-oxide. *ORs for per SD increase in log-transformed metabolites. Conditional logistic regression model was conducted by matched case-control pair, adjusting for the same covariates of model 3 in Table 4 and the interaction term between metabolites and the stratified variable. ORs and 95% CIs were obtained for each stratum. P values for interaction term were not significant except that P interaction =0.04 for choline with history of diabetes mellitus, P interaction =0.01 for betaine with history of diabetes mellitus, and P interaction =0.02 for betaine with high/low TMAO.
arrange of CVD biomarkers. [3] [4] [5] [6] Their findings have been confirmed in several independent cohorts of CVD, CKD, and diabetic patients. [8] [9] [10] [11] In 2017, a meta-analysis summarized that Treatment for diseases and potential diet and lifestyle changes after disease diagnosis may have also changed TMAO level, raising concern about reverse causation and confounding bias. Studies have found strong effects of a wide range of medications (eg, antidiabetic, antihypertensive, and NSAIDs) on modulating the gut microbiota and its metabolites. [12] [13] [14] [15] In this study, we observed inverse associations of TMAO with antihypertensive medications, NSAIDs, and self-reported dyslipidemia (possibly suggesting the use of lipid-lowering medications) and positive associations of TMAO with blood lipids-defined dyslipidemia and hs-CRP-defined chronic inflammation. It would be difficult to delineate potential influence of diseases and treatments in patient-based cohorts when a majority of participants were taking multiple medications. Therefore, the significant TMAO-CHD association observed in our study, after adjusting for metabolic conditions and medications and in subgroups of disease-free individuals, provides an important piece of epidemiologic evidence to support a potentially causal role of the TMAO pathway in the development of CVD. As a potential, novel risk factor and target for CVD prevention, it is appealing to investigate factors that influence TMAO level, especially modifiable factors such as diet. Dietary TMAO precursors choline and carnitine are abundant in red meat, poultry, eggs, dairy, and soy products. 19 However, TMAO is also a naturally occurring compound that is abundant in seafood. 20, 21 Blood and urinary levels of TMAO reflect an integrated measure of dietary intake, microbial production, and host metabolism but cannot distinguish microbialgenerated TMAO from naturally occurring seafood TMAO. Therefore, the food-TMAO associations may vary depending on individuals' habitual diets (determining TMAO food sources and the gut microbiota) and recently consumed foods that contain choline, carnitine, and/or TMAO. Evidence regarding the food-TMAO association remains limited; a few observational studies reported generally weak and possibly population-specific associations. [46] [47] [48] [49] [50] [51] Higher blood or urinary TMAO was associated with fish but not meat intake in studies conducted in France, the United Kingdom, Sweden, and Canada 46, 47, 50, 51 ; with dairy but not fish, meat, or eggs in a Germany study 49 ; and in contrast, with red meat and eggs in US studies (including the Framingham Heart Study, Yang et al., unpublished data, 2019). Among Chinese adults in Shanghai (a coastal city), we found no associations of urinary TMAO with intake of red meat, poultry, eggs, or dairy but weak associations with intake of saltwater fish and shellfish. We also found no association of TMAO with plant-based choline, despite a relatively large amount of consumption (%300 mg/ day, mostly from soy foods). 23 Of note, we observed a strong association of TMAO with deep-fried meat or fish but not with stir-fried meat or fish or deep-fried wheat or rice, suggesting that cooking methods for meat and fish may influence the TMAO level. Fried meat and fish intake has been linked with increased risks of CVD, diabetes mellitus, and cancers. [52] [53] [54] [55] [56] Our findings suggest a potential novel mechanistic explanation for the harmful health effects of fried meat and fish via the gut microbiota-related TMAO pathway. We observed that diabetes mellitus modified the associations of all TMAO-related metabolites with CHD risk. This is in line with results from some prior studies showing stronger associations of these metabolites with MACE among diabetic participants than nondiabetic participants. 5, 8 As discussed earlier, diabetes mellitus and antidiabetic medications can alter the gut microbiota, and diabetes mellitus is an established CVD risk factor. 12, 15 Thus, it is important to consider diabetes mellitus status and treatments while investigating microbial-related mechanisms in CVD. Our present study included only 68 patients with diabetes mellitus and did not collect treatment information at baseline. Future investigations into the role of TMAO in CVD development among diabetic populations are needed. We also observed that the TMAO-CHD association appeared stronger among individuals with low fiber intake (or the positive association seemed to be attenuated if fiber intake was high). Dietary fiber is a key factor in maintaining a healthy microbial community and influencing its metabolic activities. 57, 58 Studies have shown that soluble fiber, especially fermented soluble fiber, reduced TMAO production in mice fed with red meat, 59 and vegans and vegetarians (presumably having high fiber intakes) produced less TMAO than omnivores after consuming carnitine. 4 Total fiber intake was not associated with TMAO level in the current study. However, our observation of a potential diet-gut microbiota interaction on sequential risk of CHD is intriguing and worthy of future research. A major strength of our study is its prospective and population-based design. Biopecimens were collected, on average, 4 years before CHD diagnosis, and results were similar in stratified analysis by follow-up years (data not shown). All participants were free of CVD, CKD, and cancer at baseline, and the TMAO-CHD association was also significant among individuals without a metabolic condition. Thus, potential reverse causality and confounding due to diseases and treatments are minimized in our study. Furthermore, detailed information on lifestyles and diet (both usual and recent food intake) was available to the study and has rarely been considered (usually unavailable) in prior clinical studies. A major weakness of our study is a single measurement of metabolites in spot urine samples. We cannot compare urinary TMAO with previous reports that mostly measured circulating TMAO. However, plasma and creatinine-adjusted urinary TMAO are highly correlated (r=0.91), 5 and most participants in this study had no major kidney impairment (based on a urine dipstick test), so we would expect similar findings on the TMAO-CHD association if circulating TMAO were measured. Furthermore, TMAO is a product of dynamic interactions among diet, gut microbiota, and host, which may vary over time. 48, 60 Unfortunately, most population-based epidemiological studies collect only biological samples once at baseline. Repeated collections and measurements may be conducted in a subset of participants and used to calibrate biomarkers with large within-person variation. 61 Stronger associations might be observed if repeated samples were available, and measurement errors would be reduced. Finally, although our analyses were based on a priori hypotheses, chance findings due to multiple comparisons cannot be ruled out. Future replication studies are needed. In summary, elevated urinary level of TMAO is associated with a higher risk of CHD in our study among urban Chinese adults, even after adjustment for traditional CVD risk factors and among those without existing metabolic conditions. Possible interactions were observed between TMAO and diabetes mellitus history and dietary fiber intake, implying potential applications of the diet-gut microbiota-host interplay in CVD prevention.
